Posted by Michael Wonder on 07 Jun 2025
BioCryst achieves reimbursement for Orladeyo across all major European countries
6 June 2025 - Orladeyo (berotralstat) now reimbursed in the Netherlands.
BioCryst Pharmaceuticals today announced that, following a positive recommendation from the Zorginstituut Nederland, Orladeyo (berotralstat) has been approved for the routine prevention of hereditary angioedema attacks in patients aged 12 years and older.
